Similar articles for PMID: 30275213

Year	Number of Results
2008	1
2009	6
2010	4
2011	11
2012	11
2013	15
2014	14
2015	26
2016	22
2017	13
2018	15
2019	9
2020	2
2021	1

1

Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early Versus Delayed Administration.

Pasqualetti F, Gonnelli A, Molinari A, Cantarella M, Montrone S, Cristaudo A, Baldaccini D, Mattioni R, Delishaj D, Mazzotti V, Morganti R, Cocuzza P, Fabrini MG, Lombardi G, Rudà R, Soffietti R, Paiar F. Pasqualetti F, et al. Anticancer Res. 2018 Oct;38(10):5877-5881. doi: 10.21873/anticanres.12930. Anticancer Res. 2018. PMID: 30275213

2

Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.

Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, DeGroot JF. Hamza MA, et al. J Neurooncol. 2014 Aug;119(1):135-40. doi: 10.1007/s11060-014-1460-z. Epub 2014 May 7. J Neurooncol. 2014. PMID: 24803001 Free PMC article.

3

Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.

Morisse MC, Etienne-Selloum N, Bello-Roufai D, Blonski M, Taillandier L, Lorgis V, Noël G, Ahle G, Durán-Peña A, Boone M, Chauffert B. Morisse MC, et al. J Neurooncol. 2019 Sep;144(2):419-426. doi: 10.1007/s11060-019-03245-5. Epub 2019 Jul 19. J Neurooncol. 2019. PMID: 31325146

4

Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.

Hilario A, Sepulveda JM, Hernandez-Lain A, Salvador E, Koren L, Manneh R, Ruano Y, Perez-Nuñez A, Lagares A, Ramos A. Hilario A, et al. Clin Transl Oncol. 2017 Jan;19(1):51-57. doi: 10.1007/s12094-016-1502-4. Epub 2016 Mar 30. Clin Transl Oncol. 2017. PMID: 27026567

5

Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.

Piccioni DE, Selfridge J, Mody RR, Chowdhury R, Li S, Lalezari S, Wawrzynski J, Quan J, Zurayk M, Chou AP, Sanchez DE, Liau LM, Ellingson BM, Pope WB, Nghiemphu PL, Green RM, Wang HJ, Yong WH, Elashoff R, Cloughesy TF, Lai A. Piccioni DE, et al. Neuro Oncol. 2014 Jun;16(6):815-22. doi: 10.1093/neuonc/nou028. Epub 2014 Mar 13. Neuro Oncol. 2014. PMID: 24627236 Free PMC article.

6

Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.

Tabouret E, Barrie M, Thiebaut A, Matta M, Boucard C, Autran D, Loundou A, Chinot O. Tabouret E, et al. J Neurooncol. 2013 Sep;114(2):191-8. doi: 10.1007/s11060-013-1170-y. Epub 2013 Jun 12. J Neurooncol. 2013. PMID: 23756726

7

Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.

Grossmann P, Narayan V, Chang K, Rahman R, Abrey L, Reardon DA, Schwartz LH, Wen PY, Alexander BM, Huang R, Aerts HJWL. Grossmann P, et al. Neuro Oncol. 2017 Nov 29;19(12):1688-1697. doi: 10.1093/neuonc/nox092. Neuro Oncol. 2017. PMID: 28499022 Free PMC article. Clinical Trial.

8

Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.

Pasqualetti F, Pace A, Gonnelli A, Villani V, Cantarella M, Delishaj D, Vivaldi C, Molinari A, Montrone S, Pellerino A, Franchino F, Baldaccini D, Lombardi G, Lolli I, Catania F, Bazzoli E, Morganti R, Fabi A, Zagonel V, Bocci G, Fabrini MG, Rudà R, Soffietti R, Paiar F. Pasqualetti F, et al. Am J Clin Oncol. 2018 Dec;41(12):1272-1275. doi: 10.1097/COC.0000000000000464. Am J Clin Oncol. 2018. PMID: 29782366

9

Disseminated progression of glioblastoma after treatment with bevacizumab.

Bloch O, Safaee M, Sun MZ, Butowski NA, McDermott MW, Berger MS, Aghi MK, Parsa AT. Bloch O, et al. Clin Neurol Neurosurg. 2013 Sep;115(9):1795-801. doi: 10.1016/j.clineuro.2013.04.017. Epub 2013 May 21. Clin Neurol Neurosurg. 2013. PMID: 23706614 Free PMC article.

10

[Treatment of recurrent glioblastoma with single-agent bevacizumab].

Sinkó D, Nemeskéri C. Sinkó D, et al. Orv Hetil. 2016 Mar 27;157(13):500-3. doi: 10.1556/650.2015.30395. Orv Hetil. 2016. PMID: 26996897 Hungarian.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed